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Background: The bronchodilator response to short-acting b2-agonist and short-acting muscarinic
antagonist monotherapies varies on a day-to-day basis within individual patients. The objective of this
study was to compare daily variation in bronchodilator response to the combined use of albuterol and
ipratropium with monotherapies in patients with chronic obstructive pulmonary disease (COPD).
Methods: This was a 4-week, randomized, open-label, two-period crossover study in patients with COPD.
Patients were randomized 1:1 to receive albuterol via metered dose inhaler followed by ipratropium or
vice versa during treatment Period 1 (10e14 days). The order of treatments was then reversed during
treatment Period 2 (10e14 days). Pre-deﬁned efﬁcacy endpoints were: forced expiratory volume in 1 s
(FEV1), derived FEV1, inspiratory capacity (IC) and daily variability of FEV1 and IC as measured by coef-
ﬁcient of variation (CV).
Results: Albuterol and ipratropium improved FEV1 when administered as the ﬁrst bronchodilator,
compared with pre-dose values (0.269 and 0.243 L, respectively). Administration of the second bron-
chodilator provided further improvements in lung function, but to a lesser magnitude than the ﬁrst
bronchodilator (0.094 L for both treatments). A statistically signiﬁcant reduction in daily variability in
FEV1 was observed for dual bronchodilator therapy compared with monotherapy (difference in
CV ¼ 0.007; p ¼ 0.019) and pre-dose values (no treatment; difference in CV ¼ 0.022; p < 0.001).
Conclusions: The free combination of albuterol and ipratropium resulted in greater improvements and
lower day-to-day variability in FEV1 compared with either monotherapy or no bronchodilator therapy.
The reduced daily variability may be an important therapeutic advantage of using different classes of
bronchodilators in COPD.
Trial registration: NCT01691482.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Chronic obstructive pulmonary disease (COPD) is characterized
by persistent airﬂow limitation that is not fully reversible [1].
Inhaled bronchodilators form the mainstay of symptom manage-
ment in mild and moderate COPD, and include b2-agonist and
antimuscarinic therapies [2]. b2-agonists act by increasing levels of, Medicines Evaluation Unit
Manchester NHS Foundation
. Tel.: þ44 0161 946 4052;
Ltd. This is an open access article ucyclic adenosine monophosphate through stimulation of
b2-adrenergic receptors, leading to bronchodilation, while musca-
rinic antagonists bind to M3 receptors and block the bronchocon-
strictive response to cholinergic nervous stimulation [2,3].
Current COPD guidelines recommend combining bronchodila-
tors of different pharmacological classes, as this offers improve-
ments in efﬁcacy while reducing the risk of side effects that may
occur when increasing the dose of a single agent [2]. The different
and complementary bronchodilation mechanisms of muscarinic
antagonists and b2-agonists enable their use as dual bronchodilator
combination therapy. It has been shown that combining a short-
acting b2-agonist (SABA) with a short-acting muscarinic antago-
nist (SAMA) yields greater efﬁcacy in terms of forced expiratory
volume in 1 s (FEV1) than the individual monotherapies [4], andnder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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acting b2-agonists (LABAs) and long-acting muscarinic antagonists
(LAMAs) compared with monotherapies [5]. The use of dual bron-
chodilator combination therapy also decreases symptoms
compared with monotherapies [5].
The bronchodilator response to SABA and SAMAmonotherapies
varies from day-to-day within individual patients [6] and this is
likely to be associated with a corresponding variability in symp-
toms. It is not known whether dual bronchodilator therapy de-
creases this daily variation in post-bronchodilator lung function; it
is possible that a reduced response to one bronchodilator compo-
nent on a given day could be mitigated by the addition of a bron-
chodilator acting by a different mechanism, providing increased
day-to-day stability. This study was designed to test this hypothe-
sis in patients with COPD.
The primary objective of this study was to compare the daily
variation in bronchodilator response to the SABA albuterol and the
SAMA ipratropium used as monotherapies, to that with their
combined use in patients with COPD.
2. Materials and methods
2.1. Patients
Patients included in the study were 40 years of age, current or
former smokers with a smoking history of 10 pack-years (former
smokers deﬁned as those who had stopped smoking for6months
prior to Visit 1 [Screening]), a previous physician diagnosis of COPD
[1,2], a post-albuterol FEV1/forced vital capacity (FVC) ratio <0.70
and a post-albuterol FEV1 of 30% and 70% of predicted normal
values (determined by Nutrition Health and Examination Survey III
reference equations [7]). Concomitant use of inhaled corticoste-
roids at a stable dose was permitted.
Exclusion criteria included: a diagnosis of asthma, known a-1
antitrypsin deﬁciency, active lung infections (eg, tuberculosis), lung
cancer, or any other uncontrolled and clinically signiﬁcant disorder;
the use of long-term oxygen therapy; hospitalization for COPD or
pneumonia in the 12 weeks prior to Visit 1; and allergies or hy-
persensitivities to anymuscarinic receptor antagonist or b2-agonist.
Excluded medications included LAMAs, LABAs, and theophylline.
Further details of inclusion/exclusion criteria and permitted/pro-
hibitedmedications are provided in Supplementary Files 1, 2, and 3.Fig. 1. Study design (a) and example of treatment administration and spirometry timeli
A þ I, albuterol ﬁrst, followed by ipratropium; I þ A, ipratropium ﬁrst, followed by albuterThe study was conducted in accordance with the International
Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use Good Clinical
Practice guidelines, all applicable privacy requirements and the
ethical principles of the Declaration of Helsinki [8,9]. The study
protocol and any amendments were reviewed and approved by a
national, regional, or investigational center ethics committee or
institutional review board (Manchester Evaluation Unit, Man-
chester, UK: D2012-2166-E02-UK; Chesapeake institutional review
board, South Carolina, USA: PRO0007141). Written informed con-
sent was obtained from each patient prior to initiation of any study
procedures.
2.2. Study design
This was a 4-week, randomized, open-label, two-period cross-
over study performed at two study centers (one in the UK, one in
the US) between July 2012 and February 2013 (GSK study number:
DB2114956; ClinicalTrials.gov identiﬁer: NCT01691482). Patients
were randomized 1:1 to receive albuterol (GlaxoSmithKline) via
metered dose inhaler (doses: UK ¼ 4  100 mcg/puff;
US ¼ 4  90 mcg/puff) followed by ipratropium (4  20 mcg/puff;
Boehringer-Ingelheim) or vice versa during treatment Period 1. The
order of treatments was then reversed during treatment Period 2
(Fig. 1). Registration and randomization was carried out using an
interactive telephone-based system (RAMOS), with randomization
codes generated by a validated computerized system (RandAll
version 2.5). Patients were required to undergo awashout period of
up to 30 days for long-acting bronchodilator therapy prior to study
start (dependent on the speciﬁc bronchodilator), but were
permitted to continue using a stable dose of inhaled corticosteroids
during the study. Each study period consisted of 10 visits over 2
weeks (MondayeFriday) with no washout stage between Periods 1
and 2.
At each visit, pre-dose spirometry was performed, followed by
the administration of either albuterol or ipratropium. Spirometry
was repeated after 1 h, followed by the administration of the sec-
ond bronchodilator; spirometry was repeated after a further hour.
During one visit in each treatment period (Visits 5 and 15),
spirometrywas performedwithout the administration of any active
treatment to evaluate the daily variability over time of lung func-
tion without bronchodilator therapy.ne (ipratropium then albuterol) (b) A, albuterol; AE, adverse event; I, ipratropium;
ol.
Table 1
Patient baseline demographics and screening lung function and lung volumes.
Total N ¼ 56
Age, years 60.3 (7.42)
Male, n (%) 21 (38)
BMI, kg/m2 27.54 (5.45)
GOLD Grade, n (%)a
(post-hoc analysis)
A 3 (5)
B 25 (45)
Cb 1 (2)
Dc 27 (48)
Duration of COPD, n (%)
<1 year 2 (4)
1e<5 years 15 (27)
5e<10 years 25 (45)
10e<15 years 8 (14)
15e<20 years 3 (5)
20e<25 years 2 (4)
25 years 1 (2)
Current smoker, n (%) 37 (66)
Pack-years, mean (range) 47.5 (12e96)
Lung function Pre-bronchodilator
measurement
Post-bronchodilator
measurement
FEV1, L 1.230 (0.431) 1.423 (0.368)
FVC, L 2.524 (0.657) 2.929 (0.727)
Predicted FEV1 (%) 44.11 (11.62) 51.33 (9.87)
FEV1/FVC 48.85 (10.69) 49.68 (10.93)
IC, L 2.121 (0.593) 2.400 (0.620)
Reversibility, Ld 0.193 (0.188)
Reversibility (%) 19.54 (17.39)
TLC, L 5.973 (1.303)
FRC, L 3.684 (0.955)
FRC >120% hyperinﬂation,
n (%)e (post-hoc analysis)
33 (59)
Residual volume, L 2.791 (0.825)
IC, L 2.283 (0.646)
SGRQ total score 48.87 (18.19)
CAT score 20.1 (7.32)
Inhaled corticosteroids,f n (%)
Fluticasone 14 (25)
Budesonide 7 (13)
Beclometasone dipropionate 2 (4)
All data are mean (SD) unless otherwise stated.
BMI, body mass index; CAT, chronic obstructive pulmonary disease assessment test;
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FRC, functional
residual capacity; GOLD, global initiative for chronic obstructive lung disease;
IC, inspiratory capacity; SD, standard deviation; SGRQ, St. George's respiratory
questionnaire; TLC, total lung capacity.
a Based on screening CAT score.
b Patient had % predicted FEV1 30% and <50%.
c 17 patients had % predicted FEV1 30% and <50%, four patients had frequent
exacerbations, deﬁned as two exacerbations (not hospitalized) or one exacerbation
leading to hospitalization in the previous 12 months with FEV1 50%, six patients
had both % predicted FEV130% and<50% and a history of frequent exacerbations in
the last 12 months.
d Reversibility deﬁned as an increase in FEV1 of 12% and 0.200 L following
administration of albuterol.
e Hyperinﬂation deﬁned as a functional residual capacity 120% of predicted
normal values.
f Fluticasone at 100mcg (n¼ 1), 125mcg (n¼ 1), 220mcg (n¼ 2), 250mcg (n¼ 1)
and 500 mcg (n ¼ 9); Budesonide at 100 mcg (n ¼ 1); 180 mcg (n ¼ 1) and 400 mcg
(n ¼ 5); Beclometasone dipropionate at 200 mcg (n ¼ 1) and 250 mcg (n ¼ 1).
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Assessments performed during screening included: FEV1, FVC;
reversibility; total lung capacity; functional residual capacity (FRC);
inspiratory capacity (IC); St. George's Respiratory Questionnaire
score; and COPD Assessment Test. Spirometry measurements were
obtained using standardized equipment that met or exceeded the
minimal performance recommendations of the American Thoracic
Society [10]. At each study visit, patients were asked to refrain from
smoking for 1 h prior to the ﬁrst pulmonary function test and
throughout the study visit, until after the last spirometry test had
been performed. For FEV1, FVC, and IC, at least three acceptable
spirometry efforts (maximum of eight) were obtained.
The pre-deﬁned efﬁcacy endpoints were: pre-dose and post-
bronchodilator FEV1, derived FEV1 (maximal bronchodilator
response for the ﬁrst/second administered agent or combination)
and IC, and the daily variability of FEV1 and IC as measured by co-
efﬁcient of variation (CV). The proportion of patients who achieved
improvements in FEV1 above 0.100 L, 0.200 L, and 0.250 L thresholds
was also assessed, together with the proportion of days that these
thresholds were achieved. Subgroup analysis of the proportion of
study days patients failed to achieve an FEV1 improvement >0.100 L,
stratiﬁed by reversibility at screening (deﬁned as an increase in FEV1
of12% and 0.200 L following administration of albuterol), was also
performed. Safety assessments included evaluation of adverse
events (AEs) and COPD exacerbations.
2.4. Statistical analyses
No formal power calculation was performed; the sample size
was based on practical considerations and the need to recruit suf-
ﬁcient subjects to enable an estimation of CV. FEV1, derived FEV1,
and IC were analyzed using mixed models repeated measures
analysis with period, treatment, day, time, smoking status, and
center ﬁtted as ﬁxed effects and subject as a random effect. Daily
variation (CV) was analyzed using mixed models. This approach to
assessing daily variation is consistent with that employed in pre-
vious studies assessing day-to-day variability in the home-
monitoring of patients with asthma and COPD [11]. All program-
ming was performed using SAS Version 9 and S-Plus Version 7.
The efﬁcacy population (used for all efﬁcacy analyses) was
deﬁned as the population of patients who were randomized and
completed pre- and post-bronchodilator assessments for at least 17
visits, with 3 consecutive missing days. Demographic character-
istic comparisons and safety assessments were performed on the
intent-to-treat (ITT) population, deﬁned as all patients randomized
and received at least one bronchodilator treatment.
3. Results
3.1. Patients
Overall, 70 patients were screened, 56 were randomized to
treatment and 53 completed the study (Fig. 1); two patients were
withdrawn due to protocol deviations (they were unable to attend
for the visits on the required days) and one subject died. One pa-
tient in the ITT population (n ¼ 56) was excluded from the efﬁcacy
population due to missing study visits for more than 3 consecutive
days. Patient demographics and characteristics are summarized in
Table 1.
The majority of patients were female (62%) and current
smokers (66%). Forty-six percent of patients showed reversibility to
albuterol (deﬁned as an increase in FEV1 of12% and0.200 L) and
59% demonstrated hyperinﬂation (deﬁned as FRC 120% of pre-
dicted normal values).3.2. Lung function endpoints
Pre-dose, post-ﬁrst bronchodilator, and post-second broncho-
dilator lung function endpoints are summarized in Table 2 and
Fig. 2.
Albuterol and ipratropium provided improved FEV1 when
administered as the ﬁrst bronchodilator, compared with pre-dose
values (0.269 and 0.243 L, respectively). Administration of the
second bronchodilator provided further improvements in lung
function, but to a lesser magnitude than the ﬁrst bronchodilator
Table 2
FEV1, derived FEV1,a and IC for single and combination bronchodilators in the efﬁ-
cacy population (N ¼ 55).
Parameter and treatment Adjusted mean (SE) 95% CI
FEV1 (L)
Pre-dose 1.146 (0.0619) 1.022, 1.271
A 1.415 (0.0618) 1.292, 1.539
I 1.389 (0.0618) 1.265, 1.513
A þ I 1.510 (0.0621) 1.385, 1.634
I þ A 1.484 (0.0621) 1.359, 1.608
Derived FEV1 (L)
A (1H) 0.269 (0.0174) 0.235, 0.303
I (1H) 0.243 (0.0174) 0.209, 0.277
A (2H) 0.094 (0.0123) 0.070, 0.119
I (2H) 0.094 (0.0123) 0.070, 0.119
A þ I 0.363 (0.0200) 0.324, 0.403
I þ A 0.337 (0.0200) 0.298, 0.376
IC (L)
Pre-dose 1.975 (0.0856) 1.804, 2.147
A 2.243 (0.0854) 2.072, 2.414
I 2.228 (0.0854) 2.057, 2.400
A þ I 2.334 (0.0860) 2.162, 2.506
I þ A 2.311 (0.0860) 2.139, 2.484
A, albuterol; A þ I, albuterol ﬁrst, followed by ipratropium; CI, conﬁdence interval;
FEV1, forced expiratory volume in 1 s; I, ipratropium; I þ A, ipratropium ﬁrst, fol-
lowed by albuterol; IC inspiratory capacity; SE, standard error.
1H: administration of ﬁrst dose, 1 h after pre-dose assessment; 2H: administration
of second dose, 1 h after the ﬁrst dose, and 2 h after the pre-dose assessment.
a Derived FEV1: A (1H) and I (1H): FEV1 at 1H post-dose of the ﬁrst bronchodilator
minus the pre-dose FEV1; A (2H) and I (2H): FEV1 at 1H post-dose of the second
bronchodilator minus the FEV1 at 1H post-dose of the ﬁrst bronchodilator; Aþ I and
I þ A: FEV1 at 1H post-administration of the second bronchodilator minus the
corresponding pre-dose FEV1.
Fig. 2. Summary of mean daily FEV1 (a) and IC (b) for pre-dose, single and combi-
nation doses of albuterol and ipratropium. FEV1, forced expiratory volume in 1 s;
IC, inspiratory capacity.
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pattern to FEV1: albuterol and ipratropium improved IC when
administered as the ﬁrst bronchodilator (0.267 and 0.253 L,
respectively), and lesser improvements were observed when
administered as the second bronchodilator (0.083 L for albuterol;
0.091 L for ipratropium).
3.3. Daily variability
Daily variability in FEV1 response to treatment, as measured by
CV, is shown in Fig. 3, with the differences in CV after different
treatments shown in Table 3.
A statistically signiﬁcant reduced daily variability was observed
for combined dual bronchodilator therapy (FEV1 after second
bronchodilator) compared with monotherapy (FEV1 after ﬁrst
bronchodilator albuterol or ipratropium; mean CV
difference ¼ 0.007; p ¼ 0.019) and pre-dose values (mean CV
difference¼0.022; p < 0.001). Monotherapy with either albuterol
or ipratropium also resulted in less FEV1 daily variability than pre-
dose values (mean CV difference ¼ 0.015; p < 0.001).
The variability with ipratropium monotherapy was greater than
for albuterol monotherapy (mean CV difference¼ 0.013; p¼ 0.004).
The daily variability with dual bronchodilator treatment was
signiﬁcantly lower when comparedwith ipratropiummonotherapy
(p ¼ 0.028), but not when compared with albuterol monotherapy
(p ¼ 0.254). This implies that the statistically signiﬁcant difference
between dual treatment and the monotherapies was primarily
driven by the difference versus ipratropium.
IC measurements (Supplementary File 4) showed reduced CV
for measurements after the ﬁrst bronchodilator (monotherapy with
albuterol or ipratropium) compared with pre-dose values, and also
for measurements after the second bronchodilator compared with
pre-dose values (Table 3). However, dual bronchodilator treatment
did not reduce daily variability compared with monotherapy
(p ¼ 0.35).The CV of FEV1 stratiﬁed by reversibility to albuterol at
screening and the degree of hyperinﬂation at screening are pre-
sented in Supplementary File 5; the CV for pre-dose, post-ﬁrst
bronchodilator, and post-second bronchodilator FEV1 values for
reversible versus non-reversible and hyperinﬂated versus non-
hyperinﬂated patients were similar.
3.4. Thresholds of improvement
The proportion of days that patients achieved an FEV1 response
above various thresholds is summarized in Table 4.
The effects of albuterol and ipratropium monotherapies were
similar, except for the threshold of 0.100 L where there was a
numerically greater effect of albuterol. The second bronchodilator
had a minimal effect on the percentage of days with FEV1 0.100 L
compared with albuterol monotherapy (3.6% increase), while for
ipratropium monotherapy this increase was greater (8.3%). For all
other thresholds there was a beneﬁt of >10% in the number of days
that dual bronchodilator therapy achieved the threshold compared
with monotherapy. Using a threshold of 0.250 L, dual broncho-
dilator treatment resulted in ~15e20% increase in the percentage of
days on which this threshold was achieved compared with
monotherapy.
Among the 16 subjects who failed to achieve >0.100 L FEV1
improvement on albuterol at screening, we observed that
Fig. 3. Daily variability, as measured by CV, of FEV1 in the efﬁcacy population (N ¼ 55). 1H: administration of ﬁrst dose, 1 h after pre-dose assessment; 2H: administration of second
dose, 1 h after the ﬁrst dose, and 2 h after the pre-dose assessment; FEV1, forced expiratory volume in 1 s; CV, coefﬁcient of variation.
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ments above this threshold for 70.9% and 68.8% of days, respec-
tively. These subjects also achieved improvements 0.200 L for
47.2% and 50.0% of days, respectively, and 0.250 L for 33.3% and
34.7% of days, respectively.
3.5. Safety
In total, 17 patients reported an AE during the study. The most
frequent AEwas headache (n¼ 4, 7%); all other AEs occurred in2%
of patients, and no non-fatal serious AEswere reported. One subject
died during the course of the study and the cause was recorded as
‘unknown’. One patient reported a COPD exacerbation on the ﬁnal
day of Period 2, but this was resolved 3 days later.
4. Discussion
The current study demonstrates that dual bronchodilator ther-
apy with a SABA and SAMA reduces daily variation in lung functionTable 3
Treatment differences in daily variability (CV) for FEV1, and IC in the efﬁcacy pop-
ulation (N ¼ 55).
Comparison Difference in adjusted
mean (SE)
95% CI of
difference
p-value
FEV1 (L)
1H vs pre-dose 0.015 (0.0030) 0.020,0.009 <0.001
2H vs 1H 0.007 (0.0030) 0.013,0.001 0.019
2H vs pre-dose 0.022 (0.0030) 0.027,0.016 <0.001
A vs I 0.013 (0.0046) 0.022,0.004 0.004
A þ I vs I þ A 0.009 (0.0046) 0.018,0.000 0.056
A þ I vs A 0.005 (0.0042) 0.013,0.003 0.254
I þ A vs I 0.009 (0.0042) 0.017,0.001 0.028
IC (L)
1H vs pre-dose 0.010 (0.0030) 0.016,0.004 0.001
2H vs 1H 0.003 (0.0030) 0.009,0.003 0.348
2H vs pre-dose 0.013 (0.0030) 0.018,0.007 <0.001
A vs I 0.003 (0.0046) 0.012,0.006 0.530
A þ I vs I þ A 0.005 (0.0046) 0.004,0.014 0.280
A þ I vs A 0.001 (0.0042) 0.007,0.009 0.791
I þ A vs I 0.007 (0.0042) 0.015,0.002 0.112
A, albuterol; A þ I, albuterol ﬁrst, followed by ipratropium; CI, conﬁdence interval;
CV, coefﬁcient of variation; FEV1, forced expiratory volume in 1 s; I, ipratropium;
I þ A, ipratropium ﬁrst, followed by albuterol; IC, inspiratory capacity; SE, standard
error.
1H: administration of ﬁrst dose, 1 h after pre-dose assessment; 2H: administration
of second dose, 1 h after the ﬁrst dose, and 2 h after the pre-dose assessment.compared with monotherapy in patients with COPD. This suggests
that combining a beta agonist and amuscarinic antagonist together
may stabilize lung function improvements over time, which may
have important clinical signiﬁcance as less daily variation in lung
function could lead to a more consistent long-term reduction in
symptoms on a day-to-day basis [12].
The administration of dual therapy albuterol and ipratropium
increased FEV1 to a greater extent than albuterol and ipratropium
monotherapy in the present study. However, this increase was not
completely “additive” (whereby the twomonotherapy effects alone
would equal the dual bronchodilator effect), regardless of the order
of administration of albuterol and ipratropium. This lower than
fully additive effect has been previously observed in studies of dual
bronchodilationwith both short- and long-acting beta agonists and
anti-muscarinics [13,14]. This may be related to a ceiling effect,
whereby patients reach the maximum pharmacological response
achievable.
The minimal clinically important difference (MCID) for FEV1
improvement in clinical trials of an active treatment compared
with placebo in COPD is thought to be approximately 0.100 L
[15]. The addition of a second long-acting bronchodilator often
causes an improvement in trough FEV1 that is below the MCID,
compared with monotherapy [5,16,17]. The MCID values estab-
lished for bronchodilator monotherapies compared with placebo
may therefore not be applicable when considering differences
between two active therapies (ie. two bronchodilators compared
with one). Nevertheless, it is clear that combining beta-agonist
and anti-muscarinic treatments improves lung function to aTable 4
Proportion of days on which patients achieved threshold improvements in FEV1.
Percentage of days in which threshold was achieved,
mean (SD)
A (1H) I (1H) A followed
by I (2H)
I followed
by A (2H)
FEV1 change in the efﬁcacy population (n ¼ 55)
>0.100 L 81.6 (31.35) 72.9 (38.06) 85.2 (29.92) 81.2 (33.46)
>0.200 L 59.2 (38.20) 56.0 (39.54) 72.7 (35.25) 70.3 (36.23)
>0.250 L 45.9 (38.85) 45.8 (36.94) 64.0 (39.08) 59.6 (38.19)
12% and >0.200 L 58.4 (38.26) 55.4 (39.34) 71.7 (35.51) 69.1 (36.82)
A, albuterol; FEV1, forced expiratory volume in 1 s; I, ipratropium; SD, standard
deviation.
1H: administration of ﬁrst dose, 1 h after pre-dose assessment; 2H: administration
of second dose, 1 h after the ﬁrst dose, and 2 h after the pre-dose assessment.
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dilators there is evidence that this leads to consistent symptom
improvement when assessed by reliever medication usage
[5,16,17]. The current study, conducted using a SABA and SAMA,
indicates that stabilization of lung function could be a key
mechanism by which combining bronchodilators can lead to
symptom beneﬁt. It is possible that the major clinical beneﬁt of
the second bronchodilator may not be the effect size of the ab-
solute improvement in lung function, but the ability to decrease
variability in bronchodilator response between days.
The variability of the FEV1 response was not related to revers-
ibility to albuterol and hyperinﬂation status at screening. It appears
that daily variation in lung function occurs to the same degree in
patients with COPD independently of pulmonary function
characteristics.
Monotherapy with albuterol appeared to reduce FEV1 daily
variation to a greater degree than ipratropium monotherapy. As a
result, signiﬁcant improvements in daily variation were observed
for dual bronchodilator therapy versus ipratropium, but not dual
bronchodilator therapy versus albuterol. There was a numerically
greater effect with albuterol monotherapy on mean FEV1
improvement compared with ipratropium monotherapy (the
derived FEV1 values were 0.269 L and 0.243 L, respectively). This
supports the concept that greater FEV1 improvement reduces daily
variability. The mechanism responsible for the difference between
albuterol and ipratropium is unclear; we speculate that the
response to anti-muscarinics in patients with COPD may be highly
dependent on natural variations in cholinergic tone.
We used the percentage of days on which varying thresholds of
FEV1 improvement were achieved to compare the effects of dual
bronchodilator therapy and monotherapy; at the higher thresholds
(eg, >0.250 L), the advantage of dual bronchodilator therapy was
more apparent than at lower thresholds (eg, >0.100 L). This in-
dicates that a beneﬁt of dual bronchodilator therapy is to increase
the number of days on which patients have relatively large bron-
chodilator responses, rather than eradicating days where low
bronchodilator responses occur; low bronchodilator responses
(<0.100 L improvement) occurred on approximately 20e25% of
days following monotherapy, and still on approximately 15e20% of
days following dual treatment.
Interestingly, using an FEV1 threshold of 0.100 L to deﬁne non-
reversible patients at screening, we observed that subsequent im-
provements of 0.100 L after monotherapy occurred on approxi-
mately 70% of days, while improvements of 0.200 L occurred on
approximately 50% of days. This suggests that a poor response to
bronchodilator therapy on a given day does not predict that sub-
sequent responsiveness will remain low.
The CV results for IC were not as conclusive as FEV1 in terms of
the comparison of dual bronchodilator therapy compared with
monotherapy. However, the IC daily variation for dual therapy and
monotherapy were lower than pre-dose values, supporting the
concept that bronchodilator therapy stabilizes lung function.
No formal power calculation was performed for this study and
the sample size was based on practical considerations. Despite
the exploratory nature of the study in a moderate sample size,
we still identiﬁed statistically signiﬁcant differences in daily
variability of bronchodilator responses between combined
treatment and monotherapies. Long-acting bronchodilators are
being increasingly used as a mainstay of symptomatic therapy for
COPD, with dual bronchodilator LABA and LAMA combinations in
clinical development. We speculate that the ﬁndings reported
here may also apply to such long-acting dual bronchodilator
combinations, and that improved stability of lung function on a
day-to-day basis may be an important property of these
treatments.5. Conclusions
The present study showed that the free combination of albuterol
and ipratropium resulted in lower day-to-day variability in FEV1
compared with albuterol or ipratropium monotherapy. This in-
dicates that an important beneﬁt of dual bronchodilator treatment
over monotherapy is an increased ability to stabilize airway tone.
The combined use of different classes of bronchodilators is advo-
cated in current COPD guidelines [2] based on the additive im-
provements in bronchodilation that occur; we now demonstrate
that this approach can also reduce day-to-day ﬂuctuations in lung
function, which is likely to improve symptom control.
Competing interests
AC, CJK, C-QZ, and SS are employees of GlaxoSmithKline
and hold shares/stock options in GlaxoSmithKline. DS has
received sponsorship to attend international meetings, honoraria
for lecturing or attending advisory boards, and research
grants from various pharmaceutical companies including
Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Forest,
Genentech, GlaxoSmithKline, Merck, Novartis, Pﬁzer, and Takeda.
Author contributions
As corresponding author, DS is guarantor and takes re-
sponsibility for the content of the manuscript, including data and
analysis. All authors approved the ﬁnal version for submission and
agreed to be listed as authors. DS was involved in the conduct of the
study, the acquisition of data, the review and interpretation of data
and the drafting or critical revision of the manuscript. C-QZ pro-
vided statistical input and analysis, and was involved in the review
and interpretation of data and the drafting or critical revision of the
manuscript. SS, AC, and CK were involved in the planning and
conduct of the study, the acquisition of data, the review and
interpretation of data and the drafting or critical revision of the
manuscript.
Role of the funding source
GlaxoSmithKline provided support for study design, collection,
analysis, and interpretation of the data. The sponsor had no part in
the decision of the authors to submit this manuscript for publica-
tion. GlaxoSmithKline also provided funding for editing and
formatting assistance.
Acknowledgments
All authors made a substantial contribution to the study, were
involved in the drafting or critical revision of the manuscript, had
full access to study data, approved the ﬁnal version for submission,
and agreed to be listed as authors. As corresponding author, Dave
Singh is guarantor and takes responsibility for the content of the
manuscript, including data and analysis. AC, CJK, C-QZ, and SS are
employees of GlaxoSmithKline and hold shares/stock options in
GlaxoSmithKline. AC provided input into the protocol, statistical
data analysis plan, and interpretation of the data.
Stuart Wakelin and Natasha Thomas of Fishawack Indicia Ltd
provided editorial and formatting assistance in the preparation of
the manuscript, funded by GlaxoSmithKline.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.pupt.2014.08.010.
D. Singh et al. / Pulmonary Pharmacology & Therapeutics 31 (2015) 85e91 91References
[1] Celli BR, MacNee W. Standards for the diagnosis and treatment of patients
with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:
932e46.
[2] Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy
for the diagnosis, management and prevention of chronic obstructive pul-
monary disease. 2011. Available from: http://www.goldcopd.org/ [accessed
May 2014].
[3] Brusasco V. Reducing cholinergic constriction: the major reversible mecha-
nism in COPD. Eur Respir Rev 2006;15:32e6.
[4] COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmo-
nary disease, a combination of ipratropium and albuterol is more effective
than either agent alone. An 85-day multicenter trial. Chest 1994;105:1411e9.
[5] Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al.
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the
SHINE study. Eur Respir J 2013;42:1484e94.
[6] Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator
reversibility testing in chronic obstructive pulmonary disease. Thorax
2003;58:659e64.
[7] Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG. Perfor-
mance of American Thoracic Society-recommended spirometry reference
values in a multiethnic sample of adults: the multi-ethnic study of athero-
sclerosis (MESA) lung study. Chest 2010;137:138e45.
[8] International conference on harmonisation of technical requirements for
registration of pharmaceuticals for human use. ICH harmonised tripartite
guideline: guideline for good clinical practice E6(1). 1996. Available from:
http://www.ich.org/ﬁleadmin/Public_Web_Site/ICH_Products/Guidelines/
Efﬁcacy/E6_R1/Step4/E6_R1__Guideline.pdf [accessed May 2013].[9] World Medical Association (WMA). WMA declaration of helsinki - ethical
principles for medical research involving human subjects. 2008. Available
from: http://www.wma.net/en/30publications/10policies/b3/index.html
[accessed May 2013].
[10] Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.
Standardisation of spirometry. Eur Respir J 2005;26:319e38.
[11] Timmins SC, Coatsworth N, Palnitkar G, Thamrin C, Farrow CE, Schoeffel RE,
et al. Day-to-day variability of oscillatory impedance and spirometry in
asthma and COPD. Respir Physiol Neurobiol 2013;185:416e24.
[12] Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating
changes in lung function with patient outcomes in chronic obstructive pul-
monary disease: a pooled analysis. Respir Res 2011;12:161.
[13] Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison of the bron-
chodilating effects of a beta-2 adrenergic agent (Albuterol) and an anticho-
linergic agent (ipratropium bromide), given by aerosol alone or in sequence.
N Engl J Med 1986;315:735e9.
[14] Matera MG, Caputi M, Cazzola M. A combination with clinical recommended
dosages of salmeterol and ipratropium is not more effective than salmeterol
alone in patients with chronic obstructive pulmonary disease. Respir Med
1996;90:497e9.
[15] Donohue JF. Minimal clinically important differences in COPD lung function.
COPD 2005;2:111e24.
[16] Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, et al. Once-daily
umeclidinium/vilanterol 125/25 mg therapy in copd: a randomized, controlled
study. Chest 2014;145:981e91.
[17] Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Ef-
ﬁcacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
Respir Med 2013;107:1538e46.
